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Background: The 22q11.2 deletion syndrome (22q11.2DS) is caused by hemizygous microdeletions on
chromosome 22q11.2 with highly variable physical and neuropsychiatric manifestations. We explored the
genotype-phenotype relationship in a relatively large 22q11.2DS cohort treated and monitored in our clinic using
comprehensive clinical evaluation and detailed molecular characterization of the deletion.
Methods: Molecular analyses in 142 subjects with 22q11.2DS features were performed by FISH and MLPA methods.
Participants underwent clinical assessment of physical symptoms and structured psychiatric and cognitive
evaluation.
Results: Deletions were found in 110 individuals including one with an atypical nested distal deletion which was
missed by the FISH test. Most subjects (88.2%) carried the 3Mb typically deleted region and 11.8% carried 4 types of
deletions differing in size and location. No statistically significant genotype-phenotype correlations were found
between deletion type and clinical data although some differences in hypocalcemia and cardiovascular anomalies
were noted.
Analysis of the patient with the distal nested deletion suggested a redundancy of genes causing the physical and
neuropsychiatric phenotype in 22q11.2DS and indicating that the psychiatric and cognitive trajectories may be
governed by different genes.
Conclusions: MLPA is a useful and affordable molecular method combining accurate diagnosis and detailed
deletion characterization. Variations in deletion type and clinical manifestations impede the detection of significant
differences in samples of moderate size, but analysis of individuals with unique deletions may provide insight into
the underlying biological mechanisms.
Future genotype-phenotype studies should involve large multicenter collaborations employing uniform clinical
standards and high-resolution molecular methods.
Keywords: Velocardiofacial syndrome (VCFS), Multiplex ligation probe amplification (MLPA), Copy number variation
(CNV), Molecular diagnosis, Neuropsychiatric disordersBackground
The 22q11.2 deletion syndrome (22q11.2DS), also known
as velocardiofacial syndrome (VCFS) and DiGeorge syn-
drome, is a genetic disorder caused by hemizygous micro-
deletions on chromosome 22q11.2, with population
prevalence of about 1 to 4,000 births [1]. The 22q11.2DS
has multisystem manifestations including conotruncal* Correspondence: afrisch@post.tau.ac.il
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distribution, and reproduction in any mediumcongenital heart defects (CHD), velopharyngeal anomalies,
hypoparathyroidism, T-cell immunodeficiency, craniofa-
cial features, cognitive deficits and high rates of psychiatric
morbidity [e.g., schizophrenia, anxiety disorders and atten-
tion deficit hyperactivity disorder (ADHD)] [2-4]. The
clinical phenotype is characterized by variable expression
and incomplete penetrance.
The mechanism mediating 22q11.2 deletions involves
non-allelic homologous recombination of low copy
repeats (LCR) in 22q11.2. The majority (90%) of the
22q11.2 deletions are of 3Mb (encompassing ~60 genes)entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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to as typically deleted region (TDR) while 8% are 1.5Mb
in size (~28 genes) (LCR A-B). Some rare atypical dele-
tions of shorter size and in variable locations have also
been reported [5]. We have long been interested in
22q11.2DS as a model for studying the genetic contribu-
tion to psychiatric disorders and for exploring the cor-
relation between the molecular characteristics of the
deletion and the cognitive and psychiatric manifestations
in the patients.
The classic molecular diagnostic procedure used for
detection of deletions and duplications at 22q11.2 is
chromosomal analysis coupled with fluorescent in situ
hybridization (FISH) using a single fluorescent probe
(N25 or TUPLE1) located in the proximal part of the
typically deleted region. The FISH technique which is
still in routine use in many laboratories is unable to
detect deletions that are either proximal or distal to the
particular FISH probe used. In recent years several new
methods for detecting the 22q11.2 deletion have been
developed: comparative genomic hybridization (CGH)
[6,7], multiplex ligation probe amplification (MLPA)
[8,9], multiplex quantitative real-time PCR [10,11] and
high-resolution SNP microarray analysis [10,12]. The
above-mentioned whole-genome methods are still at the
research stage and require expensive equipment for per-
forming the assay and analyzing the data. The MLPA
method uses multiple probes to achieve a good reso-
lution combined with the practicality and affordability of
a commercial kit, which is rapidly and easily performed
in any experienced laboratory.
We evaluated the utility of MLPA as an alternative to
FISH in diagnosing 142 Israeli individuals who had been
referred to our clinic with the initial suspicion of
22q11.2DS and also as a tool for characterizing the dele-
tion size and location. The information of the size and
location of the deletion in the 22q11.2DS subjects is
hereby presented together with their physical and psy-
chiatric clinical features. This may help in the search for
a possible genotype-phenotype correlation of different
deletion types. The clinical phenotype of individuals with
the typically deleted region and other less common dele-
tions are compared by quantitative measures and also by
descriptive means. In addition, the physical and longitu-
dinal neuropsychiatric phenotype of an individual with a
rare short deletion is described in detail.Methods
Subjects
The study included 142 individuals referred to the Behav-
ioral Neurogenetics Center (BNC) at Schneider Children’s
Medical Center, Petah-Tikva, Israel between January 2001
and December 2009. Mean age 16.1±9.7 years; 78 males(55%) and 64 (45%) females. Sources of referral
were: (1) Individuals with FISH confirmed diagnosis of
22q11.2DS referred by clinical genetics departments in
Israel; (2) Individuals clinically suspected of the pres-
ence of 22q11.2DS, referred by cardiologists, develop-
mental pediatrics, psychiatrists and clinicians at a cleft
palate unit.
The study protocol was approved by the Rabin Medical
Center Review Board, Petah-Tikva, Israel and written
informed consent was obtained from the study partici-
pants and their parents or guardians.
Clinical evaluation
Study subjects and their parents underwent a compre-
hensive medical and developmental intake with a struc-
tured clinical checklist composed of the comprehensive
multisystem possible clinical symptoms of 22q11.2DS
and developmental history [2]. Subjects were referred
to further medical evaluations that included cardiac
check-up (including electrocardiography and echocardi-
ography), assessment for the presence of typical facial
features, evaluation of cleft anomalies (including multi-
video fluoroscopy and video endoscopy) and blood cal-
cium levels as previously described [13].
Neuropsychiatric evaluation
All subjects and their parents were interviewed by
skilled clinicians, who were trained until they achieved
satisfactory inter-rater reliability scores with the senior
investigator (D.G.), using the Hebrew version of the
Schedule for Affective Disorders and Schizophrenia for
School-Aged Children, Present and Lifetime (K-SADS-PL)
[14,15]. Adults and their parents (when available) were
interviewed with the Structured Clinical Interview for
Axis I DSM-IV Disorders (SCID) [16]. The ADHD
module from the K-SADS was added to the SCID to
evaluate the presence of ADHD.
Cognitive evaluation was conducted with the age-
appropriate versions of the Wechsler Intelligence Scale
[17,18].
Laboratory techniques
FISH analysis for 22q11.2 deletion was performed
according to standard procedures in the cytogenetic
laboratory at the Raphael Recanati Genetics Institute,
Rabin Medical Center, Israel, using the LSI TUPLE1
(HIRA) or N25 commercial probes (22q11.2) and the
LSI ARSA as a sub-telomeric 22q13.3 control probe
(Vysis Inc., Downers Grove, IL, USA).
DNA extraction
DNA from venous blood was extracted using a commer-
cial kit (Promega Corporation, Madison, WI, USA). All
DNA samples were quantified by NanoDrop ND 1000
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and stored at −70°C.
MLPA analysis
MLPA is a PCR- based method designed to detect gene
dosage abnormality by relative quantifications. The
SALSA MLPA P250-A1 DiGeorge kit (MRC-Holland,
Amsterdam, Netherlands) was used to identify copy num-
ber variations (CNVs) in the 22q11.2 region (30 probes)
and in other chromosomal regions (4q35, 8p23, 9q34,
10p15, 17p13; 18 probes) according to manufacturer's
instructions (www.mrc-holland.com). PCR amplification
products were separated by capillary electrophoresis
using ABI-Prism 3100 Genetic Analyzer (Applied Bio-
systems, Foster City, CA) at the Hy Laboratories Ltd.,
Rehovot, Israel. The data were analyzed using the Coffa-
lyser VBA analysis software V8 (http://www.mlpa.com/
coffalyser).Results
Molecular analyses
Patients were tested for a deletion in 22q11.2 by the
FISH technique as part of their routine workup upon
admission to the BNC in order to establish the diagnosis
of 22q11.2DS. The 22q11.2 deletion was detected in 109
of 140 subjects (77.8%) using either TUPLE1 (HIRA) or
N25 commercial probes. The MLPA test was performed
on all patients admitted to the BNC with suspected diag-
nosis of 22q11.2DS, irrespective of their FISH status, as a
confirmatory test to FISH and as a tool for determining
the deletion location and boundaries. Using the MLPA
P250-A1 DiGeorge kit, a 22q11.2 deletion was detected
in 110 (77.5%) of the 142 individuals examined. Duplica-
tions were not detected in any of the subjects. Additional
probes outside 22q11.2 contained in this kit (from chro-
mosomes 4q34, 8p23, 9q34.3, 10p15, 17p13.3 and 22q13)
did not reveal additional CNVs (either deletions or dupli-
cations), using a criterion of 'more than one consecutive
probe showing significant deviation from the normal
values'. A detailed graphical representation of the MLPA
analysis for 110 individuals with deletions is depicted in
Figure 1. Most subjects (97/110; 88.2%) showed a similar
pattern of deletion spanning molecular probes from
CLTCL1 to LZTR1 representing the 3Mb TDR.
The deletions in 13 individuals (11.8%) differed from
TDR and thus were referred to as non-TDR deletions.
Four subjects had a 1.5Mb deletion located between
CLTCL1 and DGCR8 probes (LCR A-B), four other sub-
jects had a deletion between CLTCL1 and PCQAP (LCR
A-C) and a larger deletion extending from CLTCL1 to
HIC2 (LCR A-D+) was identified in 4 individuals
(Figure 2). One individual (VC901) carried a short
(~1Mb) deletion between LCR B and D+.There was high agreement between the FISH and
MLPA results. All patients identified by FISH (N=109)
were confirmed by MLPA, but MLPA identified an add-
itional individual with a 22q11.2 deletion (VC901,
Figure 1, 2). This deletion could not be identified by
FISH since its starting point is distal to the FISH N25
and TUPLE1 probes (Figure 2). All individuals that were
found to be non-deleted by MLPA (N=30) were also
FISH negative.
Since the P-250 MLPA kit lacks sufficient probes in
the proximal end of the deletion we used the RT qPCR
technique as a supplementary method. We studied the
deletion status in the proximal breakpoint using SYBR
Green labeled PRODH probe and the VPREB1 probe as
a control [11]. It was found that the PRODH gene was
hemizygously deleted in most (68/71; 95.8%) subjects
tested. Out of 3 deletions that did not contain the
PRODH gene two were LCR A-D (~3Mb) and one was
LCR A-B (1.5Mb).Genotype-phenotype analysis
Tables 1 and 2 summarize the cumulative physical and
psychiatric data of the 110 subjects with 22q11.2 dele-
tions grouped according to the type of deletion. There
are 97 individuals with TDR and 13 individuals divided
into four groups of different types of non-TDR deletions.
The small number of individuals in each of the different
non-TDR deletions and the inherent variability of the
clinical data preclude rigorous statistical analysis. How-
ever, it can be seen that there are no large differences
between the groups in terms of physical and psychiatric
manifestations typical to the 22q11.2DS. It is of note that
hypocalcemia was present in 27.7% (28/101) of indivi-
duals with 3Mb and larger deletions and in none (0/8)
of the individuals with the smaller proximal deletions
(1.5 and 2Mb) (Table 1).
Table 3 gives a detailed description of the clinical data
of each the 13 non-TDR subjects. Individuals with the
1.5Mb deletion (LCR A-B) exhibited fewer cardiovascular
anomalies compared to the other non-TDR subjects (1/4,
25% vs. 8/9, 88.9%; p=0.052).Case report
Patient VC901 carried a distal LCR B-D+ deletion
located between ZNF74 and HIC2 probes (Figure 2). We
elaborate below on the clinical features of this patient
because she carried a rare deletion with only two other
similar cases in the literature [19,20] and may allow
studying the impact of the deleted genes in this patient
on its particular phenotype. Patient VC901 was referred
to our clinic at the age of 10 years as a suspected
22q11.2DS by a trained speech therapist based on her
physical and neuropsychiatric profile. FISH analysis
Figure 1 MLPA results for 110 individuals with 22q11.2 deletion. Shown below are 30 gene probes within 22q11.2 region (MLPA-P250 kit)
which were used for identifying the copy number variation. The copy number is indicated by color: red- one copy (hemizygous deletion);
white- two copies.
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individual. Patient VC901 was born with ventricular
septal defect (VSD) that was corrected by surgery, cleft
lip and palate, retrognathia, hypernasal speech, and
short stature (below the third percentile for height,
weight and head circumference). The facial features
share some similarities with 22q11.2DS (see Figure 3).
She has a broad square face, hypotelorism, narrow
nasal base and broad nasal bridge, overhanging nasal
tip, deviated nasal tip (state post cleft lip repair), short
philtrum, narrow mouth, chin dimple and broad neck.
Already at the age of 5 years she was diagnosed withdysgraphia and dyscalculia. Results on Wechsler testing
at the age of 10 years were: full scale IQ 59 (verbal IQ
69, performance IQ 55). Psychiatric assessment at the
age 13 years conducted by K-SADS indicated that Pa-
tient VC901 is suffering from severe anxiety disorders
including generalized and separation anxiety disorders
and specific and social phobias. In addition Patient
VC901 was coping with ADHD, predominantly in-
attentive type. She also exhibited bizarre behaviors which
were diagnosed as subthreshold psychotic symptoms.
On second evaluation at the age of 20 years Patient
VC901 was diagnosed with psychotic disorder not
Figure 2 Schematic representation of 22q11.2 deletions detected by MLPA. Genes marked in blue contain MLPA P250-A1 probes.
A typically deleted region (TDR) is indicated in red; non-TDR deletions are presented by other colors. FISH probes – N 25 and TUPLE1 (HIRA) are
indicated by stars.
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and recurrent episodes in which she threatened to stab
her parents with a knife, with a Positive and Negative
Syndrome Scale (PANSS) score of 89. Her cognitive
performance showed some improvement compared to
the first evaluation with full scale IQ score 67 (verbal
IQ 73, performance IQ 65).Individuals with no detected deletion
In 32 (22.5%) of 142 subjects referred to the BNC with
suspicion of 22q11.2DS no deletions were detected
either by MLPA or by FISH. To illustrate the problematic
diagnosis of subjects showing some 22q11.2DS-like
phenotype but with no apparent deletion we selected 12
individuals with the most pronounced clinical manifesta-
tions typical to 22q11.2DS and present them in Table 4.Table 1 Clinical data for 22q11.2DS subjects - Physical featur
Deletion type Cardiovascular anomalies Palate a
LCR A-D (TDR) 67/97(0.69) 80/9
LCR A-B (~1.5 Mb) 1/4 (0.25) 3/4
LCR A-C (~2 Mb) 3/4 (0.75) 3/4
LCR A-D+ 4/4 (1.00) 4/4
LCR B-D+ 1/1 (1.00) 1/1Interestingly, it appears that the variety and severity of
the clinical symptoms in these subjects are very similar
to those found in confirmed 22q11.2DS patients.Discussion
Analyzing a relatively large 22q11.2DS cohort allowed us
to compare the FISH and MLPA methods, perform mo-
lecular analysis of the 22q11.2 deletion in our patients
and examine the phenotype-genotype relationship.
The MLPA technique confirmed all the deletions that
were previously detected by FISH in our patients while
the FISH assay failed to detect one atypical deletion be-
cause it was outside the location of the FISH probes.
Thus the MLPA is clearly superior to FISH as a diag-
nostic tool and a useful method for deletion char-
acterization, essential for genotype-phenotype analysis.es
bnormality Facial dysmorphology Hypocalcemia
7 (0.82) 85/87 (0.98) 27/97 (0.28)
(0.75) 4/4 (1.00) 0
(0.75) 4/4 (1.00) 0
(1.00) 4/4 (1.00) 1/4 (0.25)
(1.00) 0 0
Table 2 Clinical data for 22q11.2DS subjects - Psychiatric and cognitive features
Deletion Age [years]
Mean ±SD (N)
VIQ PIQ FIQ Psychosis ADHD MDD Anxiety
disorders
OCD ASDs
Mean ±SD (N) SZ SZaff Psychotic
dis. NOS
LCR A-D 3Mb (TDR) 17.39±10.1 (97) 77.5±12.6 (81) 76.2±13.6 (80) 74.2±12.5 (82) 7/80 (0.09) 1/80 (0.01) 3/80 (0.04) 36/80 (0.45) 8/80 (0.10) 32/80 (0.40) 8/80 (0.10) 3/69 (0.04)
LCR A-B (~1.5 Mb) 20.50±17.41 (4) 81.0+18.0 (3) 73.0±14.0 (3) 75.0+16.8 (3) 0 1/4 (0.25) 0 2/4 (0.50) 0 1/4 (0.25) 0 0
LCR A-C (~2 Mb) 17.00±15.56 (4) 79.7+8.5 (3) 70.0±2.0 (3) 68.8±6.5 (4) 0 0 0 3/4 (0.75) 0 2/4 (50) 0 0
LCR A-D+ 11.25±2.63 (4) 79.3+11.4 (4) 75.3±12.3 (4) 75.0±10.5 (4) 0 0 0 4/4 (1.00) 1/4 (0.25) 2/4 (0.50) 1/4 (0.25) 0
LCR B-D+ 20 69 55 59 0 0 1 1/1 (1.00) 0 1/1 (1.00) 0 0
VIQ, PIQ and FIQ – verbal, performance and full IQ, respectively, SZ - Schizophrenia, SZaff - Schizoaffective Disorder, Psychotic dis. (NOS) - Psychotic Disorder Not Otherwise Specified, ADHD - Attention Deficit






























VC671 16 LCR A-B
(~1.5 Mb)
MDD GAD No Eyes, ears, chin, nose Cleft palate
VC672 46 LCR A-B
(~1.5 Mb)
Schizoaffective disorder No Chin No
VC1081 7 LCR A-B
(~1.5 Mb)





VC1161 13 LCR A-B
(~1.5 Mb)








PFO, hemitruncus atresia of
Rt pulmonary, high origin of
Lt pulmonary artery from





VC201 13 LCR A-C (~2
Mb)
ADHD, Specific phobia Rt aortic arch with aberrant left







VC641 7 LCR A-C (~2
Mb)
ADHD VSD, ASD - spontaneous closure,





VC871 8 LCR A-C (~2
Mb)
ADHD No Eyes, ears, nose, face Occult
submucous
cleft palate
VC431 10 LCR A-D+ ADHD, OCD Small VSD- spontaneously closed.



















VC1621 15 LCR A-D+ ADHD, MDD Bicuspid aortic valve Eyes, mouth, face Occult
submucous
cleft palate
VC901 20 LCR B-D+ Psychotic dis. (NOS), ADHD,
GAD, SA, Specific and
Social phobia




ADHD- Attention Deficit Hyperactivity Disorder, GAD- Generalized Anxiety Disorder, MDD- Major Depressive Disorder, PTSD- Posttraumatic Stress Disorder, VSD-
Ventricular Septal Defect, ASD- Atrial Septal Defect, PDA- Patent Ductus Arteriosus, PFO- Patent Foramen Ovale SA- Separation Anxiety Disorder, Psychotic dis.
(NOS) - Psychotic Disorder Not Otherwise Specified.
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deletions but their costs are substantially higher. Other
studies have recommended using MLPA as a diagnostic
tool [8,21]. However, MLPA is limited in identifying the
deletion boundary that is determined by the availability
of probes in the deletion breakpoints. The MLPA kit that
we used (P250-A1) lacked probes in the candidate
PRODH gene located in the proximal breakpoint which
was found to be associated with psychotic disorders in
22q11.2DS [22,23]. To solve this problem we used qPCR
technique and found that the PRODH gene was deleted
in most (94.4%) of the 22q11.2DS individuals, as was
found previously [6,24]. The MLPA kit released after weperformed our study (P324-A2) already contained several
PRODH gene probes.Molecular characteristics of the 22q11.2 deletion
We identified 5 types of 22q11.2 deletions. According to
the results of the specific MLPA kit used, the proximal
starting point for all deletions, except one, was located
in the CLTCL1 gene probe, near LCR A (Figure 2). The
distal breakpoints of the deletions were located in LCRs
B, C, D and D+ thus determining the size and location
of the deletions. Ninety seven out of 110 individuals
(88.2%) carried the typical ~3Mb deletion (LCR A-D)
Figure 3 Facial appearance of Patient VC901 with atypical
22q11.2 deletion. Note the broad square face, hypotelorism,
narrow nasal base and broad nasal bridge, overhanging nasal tip,
deviated nasal tip (state post cleft lip repair), short philtrum, narrow
mouth, chin dimple and broad neck.
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(77–88.7%) [20,21,24-27].
The largest deletion (LCR A-D+), a variant of the
3Mb deletions, was present in 3.63% of the subjects
compared to 4.5-6.5% in previous reports [8,24]. The
prevalence of the proximal deletions of 1.5Mb (LCR A-B)Table 4 Clinical data of individuals without 22q11.2 deletion
ID Age Gender Palate abnormality Card
VC411 11 F Occult submucous cleft palate
VC561 19 F Occult submucous cleft palate
VC611 19 M Occult submucous cleft palate
VC631 14 F Occult submucous cleft palate
VC761 24 F Submucous cleft palate
VC861 13 M Cleft palate VSD, h
VC941 5 M Velopharyngeal insufficiency
VC951 10 M Hypernasal speech
VC1021 23 F Occult submucous cleft palate
VC1031 11 M Hypernasal speech
VC1201 15 F Cleft palate
VC1464 7 F Palate insufficiency PFO
VSD- Ventricular septal defect, ASD- Atrial septal defect, TOF - Tetralogy of Fallot, PDand 2Mb (LCR A-C), each 3.63% in our subjects, varied
largely in other studies [20,21,24-27], probably due to
different sample sizes and resolution of the mapping
methods used.
Genotype-phenotype relationship
Studying the genotype-phenotype relationship in 22q11.
2DS is a formidable task. The difficulties are obvious:
there are up to 200 possible clinical symptoms [4], the
clinical variability is large even in individuals with the
same type of deletion and the statistical power is low
because most individuals harbor the common 3Mb
TDR and only a few with other entities. Yet, it can po-
tentially shed light on the role of the genes that contrib-
ute to the physical and psychiatric symptoms expressed
in this disorder. The quantitative comparison between
97 individuals with TDR and those with four different
types of nonTDR deletions along several physical and
neuropsychiatric-cognitive parameters did not reveal
statistically significant differences. This could be due to
methodological limitations such as sample size, and the
complexity of the genetic and epigenetic mechanisms
governing the phenotype in 22q11.2DS. Our results are
supported by most previous studies that could not dem-
onstrate a correlation between the size and the location
of the deletion and the clinical features of the subjects
[24,25,28-30]. However, Rauch et al. (2005) demon-
strated a correlation between deletion characteristics
and phenotypic expression by assessment of individuals
with typical and atypical 22q11.2 deletions, showing
that atypical CHD and mild dysmorphism are
recognizable feature of atypical distal deletions [20]. Re-
cently, a case-report of monozygotic twins differing in
their deletion size and clinical expression was published,
indicating a possible role of deletion characteristics for
the phenotype [31].iovascular anomalies Facial dysmorphology Hypocalcemia
VSD Eyes, chin, face No
TOF Eyes, mouth, nose, face No
Aortic stenosis Eyes, mouth, face Yes
VSD Eyes, mouth, chin, face No
PDA Eyes, mouth, nose, face No
ypoplastic left ventricle Eyes, nose, face No
VSD Mouth No
VSD Nose, face No
Truncus arteriosus Eyes, mouth, ears, chin Yes
ASD Mouth, nose, face No
Aortic stenosis Face No
, Pulmonary stenosis Mouth, chin, nose Yes
A- Patent ductus arteriosus, PFO- Patent foramen ovale.
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was found in 27.7% of patients with large deletions
(3Mb, LCR A-D and LCR A-D+) but was absent in
those carrying the proximal nested deletions (1.5 and
2Mb). Interestingly, neither was it observed in patients
with distal nested deletions [33]. Although the number
of cases is small, this observation may suggest that
haploinsufficiency of genes both at the proximal and
the distal part of 22q11.2 is required in order to cause
hypocalcemia.
The presented clinical data of each individual carrying
a non-TDR deletion are not in themselves informative
but may be of help in the effort to build a common data
base. More informed and educated conclusions could be
made on this intriguing question by applying unified
molecular methods for mapping the 22q11.2 deletion
(high resolution methods such as CGH and SNP arrays
and next generation sequencing) and using agreed clin-
ical parameters and scoring system for characterizing
the phenotype.Individuals without 22q11.2 deletion
Before the era of molecular diagnosis patients were diag-
nosed as VCFS (22q11.2DS) solely based on their clinical
symptoms. When molecular genetics methods were
introduced it turned out that in about 20% of the
patients classified as VCFS no deletion could be detected
[20,21] and the question of the etiology of their pheno-
type is still unknown. Interestingly, when we examined a
subgroup of these individuals it appeared that the variety
and severity of clinical symptoms in these subjects are
very similar to those found in confirmed 22q11.2DS
patients. Subjects may have been misdiagnosed because
they had a combination of relatively common symptoms,
such as cardiac anomalies and neuropsychiatric disorders,
that when considered together phenocopy the 22q11.2DS.
It is also possible that these patients do carry very small
deletions or even point mutations which are below the
resolution of the methods used or they have other micro-
deletion or microduplication syndromes.The case with atypical nested distal deletion
Patient VC901 carries a rare, small deletion that does
not include the nested proximal 1.5Mb region which
harbors several important candidate genes, thought to
be sufficient for producing the syndrome [34]. This case
portrays the complexity of the molecular mechanisms
controlling the 22q11.2DS phenotype, indicating the
possibility of redundancy in causative genes. Since the
"classical" candidate genes are not deleted in this person
other candidate genes residing in the nested distal region
may be responsible for the physical features and neuro-
psychiatric manifestations. For example, of the candidategenes that have been shown to be involved in cardiac
malformations (HIRA, UFD1L, TBX1 and CRKL) [35-39]
CRKL is one that is located in the distal deletion region
and has been found to affect cardiac neural crest deriva-
tives in mice [36]. Its loss may be the causative event for
the CHD in this case. In a similar manner, the neuro-
psychiatric phenotype may be affected by the deletion of
PIK4CA and SNAP29 from the distal region which have
been demonstrated to be associated with schizophrenia
[40-43], and not by the putative schizophrenia genes
PRODH, COMT, DGCR8 and ZDHHC8. Another genetic
mechanism that may affect the phenotype involves
control elements in the deleted region that act by cis
mechanisms on the expression of the non-deleted can-
didate genes as in the dosage-sensitive interaction be-
tween Tbx1and Crkl in mice [44].
The longitudinal neuropsychiatric follow-up of this
patient has raised the intriguing question of whether
multiple genes in the 22q11.2 region are responsible for
the emergence of schizophrenia in 22q11.2DS patients.
Her psychiatric developmental trajectory is typical of
22q11.2DS namely, anxiety and subthreshold positive
psychotic symptoms during childhood evolving to a full
psychotic disorder in adulthood. Yet her cognitive devel-
opmental trajectory is not typical, as her IQ scores did
not decline and even improved a little during young
adulthood, whereas in typical 22q11.2DS patients there is
a cognitive decline especially of verbal IQ [45, 46]. This
might suggest that the neuropsychiatric manifestations in
22q11.2DS are governed by several sets of genetic ele-
ments. It is tempting to speculate that genes such as
PIK4CA and SNAP29 that are deleted in our patient may
be involved in the emergence of psychotic "positive
symptoms" while others, such as PRODH and COMT
that are not deleted, play a role in the cognitive decline
process.
Two other 22q11.2DS cases with similar distally nested
deletion have been reported but they are not readily
comparable to the present case because of the probands'
young age. One was a patient with TOF and facial dys-
morphology, last assessed at 9 months of age [19], and
the other a 6 year-old with typical facial features, signifi-
cant developmental delay and increased anxiety suggest-
ive of possible early signs of psychiatric illness [20].Conclusions
The MLPA method was accurate and efficient in
diagnosing 22q11.2DS in our patients and in defining
ambiguous cases. In our opinion, for a mid-size labora-
tory it represents the best choice as an intermediary tech-
nique between the classical FISH method and the high
throughput methods such as CGH, SNP arrays and deep
sequencing.
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http://www.biomedcentral.com/1471-2350/13/122Although the quantitative genotype-phenotype corre-
lations in our cohort were not statistically significant,
the clinical data presented may be added to the body of
evidence continually accumulating by interested scien-
tists. Individuals with unique deletions may shed light
on specific issues as in the case of patient VC901. Her
case suggests that there is redundancy of genes causing
physical and neuropsychiatric phenotype in 22q11.2DS
and that the psychiatric and cognitive trajectories may
be governed by different genes.
We believe that the study of the genotype-phenotype
correlation would be best conducted using a compre-
hensive approach of creating a multicenter consortium
that will establish a large data base of patients to be
characterized by uniform clinical standards and by state-
of-the art molecular methods.
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